3 weeks ago
Gland Pharma, Neuland Laboratories announce long-term CDMO partnership
Two medicine-making companies in India decided to become partners.
One company is called Gland Pharma, and it is known for making sterile medicines.
The other company is called Neuland Laboratories, and it is very good at making complex medicine ingredients, called APIs.
Under the new partnership, Gland Pharma will build a special sterile manufacturing suite to produce some of these ingredients.
The ingredients will be used for microparticle depot products, which are medicines that release their effect slowly over time.
By working together, the two companies can serve customers all over the world.
Their leaders said the partnership combines the best skills of both companies.
They believe it will bring high quality, reliability, and a steady supply of medicines.
This is good news for companies that make and use these medicines.
Gland Pharma Limited and Neuland Laboratories Limited announced a long-term strategic CDMO partnership.
Under the partnership, Gland Pharma will establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products.
The collaboration combines Neuland Laboratories' complex API development and manufacturing expertise with Gland Pharma's global sterile manufacturing capabilities and regulatory compliance track record.
Srinivas Sadu, Executive Chairman of Gland Pharma, said the partnership provides a robust, scalable CDMO solution backed by world-class quality, compliance, and manufacturing excellence.
Saharsh Davuluri, CEO of Neuland Laboratories, said the partnership strengthens delivery of quality, reliability, and supply assurance for global customers.
- Who
- Gland Pharma Limited and Neuland Laboratories Limited, two pharmaceutical companies
- What
- Announced a long-term strategic CDMO partnership under which Gland Pharma will establish a sterile manufacturing suite for APIs pertaining to microparticle depot products
- Where
- The announcement was reported from Hyderabad
- When
- A specific date was not mentioned in the article
- Why
- To serve growing worldwide demand for sterile APIs by combining Neuland's complex API expertise with Gland's sterile manufacturing capabilities
Key facts
- Companies involved
- Gland Pharma Limited and Neuland Laboratories Limited
- Partnership type
- Long-term strategic CDMO partnership
- Gland Pharma's commitment
- Establish a sterile manufacturing suite for APIs pertaining to microparticle depot products
- Neuland's expertise
- Complex API development and manufacturing
- Gland Pharma's expertise
- Global sterile manufacturing and regulatory compliance track record
- Gland Pharma executive
- Srinivas Sadu, Executive Chairman
- Neuland executive
- Saharsh Davuluri, CEO
Quotes
Saharsh Davuluri
CEO, Neuland Laboratories
“Through this partnership with Gland Pharma, we are combining Neuland’s expertise in complex APIs with Gland’s proven sterile manufacturing capabilities to create a differentiated platform for global customers. Together, we are strengthening our ability to deliver the quality, reliability, and supply assurance that innovators and generic companies expect from their CDMO partners.”
thehansindia.com
“By leveraging the complementary strengths of both organizations, we will provide a robust and scalable CDMO solution backed by world‑class quality, compliance and manufacturing excellence. We believe this partnership creates a strong foundation for sustainable growth and long‑term value creation for our customers and both organizations.”
thehansindia.com










